Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 64

Sort by

Sort Order Select

Journal Articles

Treatment outcomes of complement protein C5 inhibition in 509 UK patients with paroxysmal nocturnal hemoglobinuria

Richard J. Kelly, Matthew Holt, Jennifer Vidler, Louise M. Arnold, Joanna Large, Briony Forrest, Catherine Barnfield, Alexandra Pike, Morag Griffin, Talha Munir, Petra Muus, Sateesh K. Nagumantry, Abraham Varghese, John R. Davies, Roochi Trikha, Austin G. Kulasekararaj, Lindsay Mitchell, Shreyans Gandhi

Blood (2024) 143 (12): 1157–1166.

https://doi.org/10.1182/blood.2023021762

Published: 2024

Journal Articles

AI for AA: machine learning makes an entry

Austin G. Kulasekararaj

Blood (2023) 141 (17): 2040–2042.

https://doi.org/10.1182/blood.2022019444

Published: 2023

Journal Articles

Consensus proposal for revised International Working Group 2023 response criteria for higher-risk myelodysplastic syndromes

Blood (2023) 141 (17): 2047–2061.

https://doi.org/10.1182/blood.2022018604

Published: 2023

Includes: Supplemental data

Journal Articles

Germ line DDX41 mutations define a unique subtype of myeloid neoplasms

Hideki Makishima, Ryunosuke Saiki, Yasuhito Nannya, Sophia Korotev, Carmelo Gurnari, June Takeda, Yukihide Momozawa, Steve Best, Pramila Krishnamurthy, Tetsuichi Yoshizato, Yoshiko Atsuta, Yusuke Shiozawa, Yuka Iijima-Yamashita, Kenichi Yoshida, Yuichi Shiraishi, Yasunobu Nagata, Nobuyuki Kakiuchi, Makoto Onizuka, Kenichi Chiba, Hiroko Tanaka, Ayana Kon, Yotaro Ochi, Masahiro M. Nakagawa, Rurika Okuda, Takuto Mori, Akinori Yoda, Hidehiro Itonaga, Yasushi Miyazaki, Masashi Sanada, Takayuki Ishikawa, Shigeru Chiba, Hisashi Tsurumi, Senji Kasahara, Carsten Müller-Tidow, Akifumi Takaori-Kondo, Kazuma Ohyashiki, Toru Kiguchi, Fumihiko Matsuda, Joop H. Jansen, Chantana Polprasert, Piers Blombery, Yoichiro Kamatani, Satoru Miyano, Luca Malcovati, Torsten Haferlach, Michiaki Kubo, Mario Cazzola, Austin G. Kulasekararaj, Lucy A. Godley, Jaroslaw P. Maciejewski, Seishi Ogawa

Blood (2023) 141 (5): 534–549.

https://doi.org/10.1182/blood.2022018221

Published: 2023

Includes: Supplemental data

Journal Articles

Phase 2 study of danicopan in patients with paroxysmal nocturnal hemoglobinuria with an inadequate response to eculizumab

Austin G. Kulasekararaj, Antonio M. Risitano, Jaroslaw P. Maciejewski, Rosario Notaro, Peter Browett, Jong Wook Lee, Mingjun Huang, Michael Geffner, Robert A. Brodsky

Blood (2021) 138 (20): 1928–1938.

https://doi.org/10.1182/blood.2021011388

Published: 2021

Includes: Supplemental data

Journal Articles

Two Currently Recruiting Randomized Phase III Trials: COMMODORE 1 and 2 Evaluating Crovalimab Vs Eculizumab in Patients with Paroxysmal Nocturnal Hemoglobinuria with or without Current Anti-Complement Therapy

Austin G. Kulasekararaj, Antonio Risitano, Alexander Roeth, Guangsheng He, Jeffrey Pu, Lilyan Wright, Anita Appius, Alexandre Sostelly, Sasha Sreckovic, Sven F Stanzel, Talha Munir, Jun-Ichi Nishimura

Blood (2021) 138 (Supplement 1): 4313.

https://doi.org/10.1182/blood-2021-152306

Published: 2021

Journal Articles

NGS Evaluation of the Eqol-MDS Trial: Preliminary Analysis of Eltrombopag for Thrombocytopenia of Low-Risk MDS

Esther Natalie Oliva, Corrado Mammi', Maria Cuzzola, Yasuhito Nannya, Austin G. Kulasekararaj, Maria Grazia D'Errigo, Maria Concetta Cannatà, Gina Zini, Roberto Latagliata, Pasquale Niscola, Valeria Santini, Marta Riva, Isabella Capodanno, Sabrina Greve, Alexander E Smith, Seishi Ogawa

Blood (2021) 138 (Supplement 1): 1516.

https://doi.org/10.1182/blood-2021-150619

Published: 2021

Journal Articles

Immunogenicity of Covid-19 Vaccination in Subjects with Myelodysplastic Syndromes

Jennifer Vidler, Thanussuyah Alaguthurai, Sultan Abdul-Jawad, Sivalekha Viramuthu, Richard Beatson, Rosalind Graham, Sheeba Irshad, Austin G. Kulasekararaj, Piers EM Patten

Blood (2021) 138 (Supplement 1): 3696.

https://doi.org/10.1182/blood-2021-152401

Published: 2021

Journal Articles

Predictors for Improvement in Patient-Reported Outcomes: Post-Hoc Analysis of a Phase 3 Randomized, Open-Label Study of Eculizumab and Ravulizumab in Complement Inhibitor-Naïve Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH)

Hubert Schrezenmeier, Austin G. Kulasekararaj, Lindsay Mitchell, Regis Peffault De Latour, Timothy Devos, Shinichiro Okamoto, Richard Wells, Karissa Johnston, Evan Popoff, Antoinette Cheung, Jimmy Wang, Philippe Gustovic, Alice Wang, Ioannis Tomazos, Yogesh Patel, Jong Wook Lee

Blood (2021) 138 (Supplement 1): 2196.

https://doi.org/10.1182/blood-2021-144554

Published: 2021

Journal Articles

Ravulizumab (ALXN1210) vs eculizumab in C5-inhibitor–experienced adult patients with PNH: the 302 study

Austin G. Kulasekararaj, Anita Hill, Scott T. Rottinghaus, Saskia Langemeijer, Richard Wells, F. Ataulfo Gonzalez-Fernandez, Anna Gaya, Jong Wook Lee, Emilio Ojeda Gutierrez, Caroline I. Piatek, Jeff Szer, Antonio Risitano, Shinji Nakao, Eric Bachman, Lori Shafner, Andrew I. Damokosh, Stephan Ortiz, Alexander Röth, Regis Peffault de Latour

Blood (2019) 133 (6): 540–549.

https://doi.org/10.1182/blood-2018-09-876805

Published: 2019

Includes: Supplemental data

Journal Articles

A Review of 1000 Molecular Investigations of Rare Inherited Anaemia and Related Conditions with the Red Cell Gene Panel

Rachel Mayhew, Frances Smith, Laura Steedman, Nicholas Parkin, Eva Moldes Beiro, Peter Rushton, Alison Bybee, David Brawand, Judith Marsh, Austin G. Kulasekararaj, MBBS, MD MRCP, FRCPath, Shreyans Ghandi, Sahar Mansour, Ghulam Mufti, Antonio Pagliuca, Subarna Chakravorty, David C Rees, Barnaby Clark

Blood (2018) 132 (Supplement 1): 3609.

https://doi.org/10.1182/blood-2018-99-118799

Published: 2018

Journal Articles

Efficacy of Eculizumab in Pediatric Patients with Paroxysmal Nocturnal Hemoglobinuria in the International PNH Registry

Álvaro Urbano-Ispizua, MD PhD, Austin G. Kulasekararaj, MBBS, MD MRCP, FRCPath, Marije Bartels, MD PhD, Christopher J. Patriquin, MD MSc, FRCPC, Britta Hoechsmann, MD, Alexey A. Maschan, MD, Amanda Wilson, PhD, Philippe Gustovic, MD, Hubert Schrezenmeier, MD

Blood (2018) 132 (Supplement 1): 3614.

https://doi.org/10.1182/blood-2018-99-111306

Published: 2018

Journal Articles

Prognostic Value of Clone Size in Paroxysmal Nocturnal Hemoglobinuria (PNH) for Thrombotic Events in Untreated Patients in the International PNH Registry

Regis Peffault De Latour, Jaroslaw P. Maciejewski, Austin G. Kulasekararaj, MBBS, MD MRCP, FRCPath, Loree Larratt, MD FRCP(C), Ronald S. Go, MD, David Dingli, MD PhD, Amanda Wilson, PhD, Philippe Gustovic, MD, Aleksandr Kulagin

Blood (2018) 132 (Supplement 1): 1038.

https://doi.org/10.1182/blood-2018-99-111324

Published: 2018

Journal Articles

Long-Term Follow-up of the Randomized Controlled Study in Patients with Newly Diagnosed Severe Aplastic Anemia Treated with ATG, Cyclosporine, with or without G-CSF: On Behalf of the SAA Working Party of the EBMT

André Tichelli, MD, Regis Peffault De Latour, Jakob R. Passweg, MD PhD, Cora Knol, Gérard Socié, MDPhD, Judith Marsh, Britta Hoechsmann, MD, Hubert Schrezenmeier, MD, Andrea Bacigalupo, MD, Sujith Samarasinghe, Alicia Rovo, MD, Austin G. Kulasekararaj, MBBS, MD MRCP, FRCPath, Dirk-Jan Eikema, Paul Bosman, Peter Bader, MD PhD, Antonio M. Risitano, MD PhD, Carlo Dufour, MD

Blood (2018) 132 (Supplement 1): 1307.

https://doi.org/10.1182/blood-2018-99-111811

Published: 2018

Journal Articles

A Prospective Analysis of Breakthrough Hemolysis in 2 Phase 3 Randomized Studies of Ravulizumab (ALXN1210) Versus Eculizumab in Adults with Paroxysmal Nocturnal Hemoglobinuria

Robert A. Brodsky, MD, Regis Peffault De Latour, Scott T. Rottinghaus, MD, Alexander Röth, MD, Antonio M. Risitano, MD PhD, Ilene C. Weitz, MD, Peter Hillmen, MB ChB, PhD FRCP, FRCPath, Jaroslaw P. Maciejewski, Jeffrey Szer, MBBS, Jong-Wook Lee, MD PhD, Austin G. Kulasekararaj, MBBS, MD MRCP, FRCPath, Lori Volles, MD, Andrew I. Damokosh, PhD, Stephan Ortiz, RPh, PhD, Lori Shafner, PhD, Anita Hill, MD PhS, Hubert Schrezenmeier, MD

Blood (2018) 132 (Supplement 1): 2330.

https://doi.org/10.1182/blood-2018-99-110874

Published: 2018

Journal Articles

Results from a Phase 3, Multicenter, Non-Inferiority Study of Ravulizumab (ALXN1210) Versus Eculizumab in Adult Patients with Paroxysmal Nocturnal Hemoglobinuria Currently Treated with Eculizumab

Austin G. Kulasekararaj, MBBS, MD MRCP, FRCPath, Anita Hill, MD PhS, Scott T. Rottinghaus, MD, Saskia Langemeijer, MD PhD, Richard A. Wells, MD DPhil, F. Ataulfo Gonzalez-Fernandez, Anna Gaya, Jong-Wook Lee, MD PhD, Emilio Ojeda Gutierrez, Caroline I. Piatek, Jeffrey Szer, MBBS, Antonio M. Risitano, MD PhD, Shinji Nakao, MD PhD, Eric Bachman, Lori Shafner, PhD, Andrew I. Damokosh, PhD, Stephan Ortiz, RPh, PhD, Alexander Röth, MD, Regis Peffault De Latour

Blood (2018) 132 (Supplement 1): 625.

https://doi.org/10.1182/blood-2018-99-119147

Published: 2018

Journal Articles

Prognostic and Predictive Impact of Small PNH Clones in a Large Cohort of Patients with Myelodysplastic Syndromes and Aplastic Anemia: A Single-Center Experience

Bruno Fattizzo, MD, Alan Dunlop, Robin M. Ireland, FRCP, Shireen Kassam, MD, Dario Consonni, MD, Deborah Yallop, MBBS FRCP FRCPath PhD, Ghulam J. Mufti, Judith Marsh, Alberto Zanella, MD, Wilma Barcellini, MD, Austin G. Kulasekararaj, MBBS, MD MRCP, FRCPath

Blood (2018) 132 (Supplement 1): 3870.

https://doi.org/10.1182/blood-2018-99-116772

Published: 2018

Journal Articles

Neoantigens in MDS Are Associated with Two Novel CD4+ T Cell Subsets and Improved Overall Survival

Thomas Coats, MD, Alexander E Smith, PhD, Athanasios Mourikis, Tala Shahin, Austin G. Kulasekararaj, MBBS, MD MRCP, FRCPath, Steve Best, PhD, Sneha Chitre, Richard Ellis, Nedyalko Petrov, Susanne Heck, Jonathan Michael Irish, PhD, Shahram Kordasti, MD PhD, Ghulam Mufti, DM, FRCP, FRCPath

Blood (2017) 130 (Supplement 1): 2958.

https://doi.org/10.1182/blood.V130.Suppl_1.2958.2958

Published: 2017

Journal Articles

Low-Dose Second Generation TKI Is an Effective Approach to Reduce TKI Related Side Effects and Toxicity While Preserving Molecular Response in CML Patients with TKI Intolerance

Varun Mehra, MRCP, FRCPath, Titilola Oyebamiji, Stefanie Widya, Robin M. Ireland, FRCP, Austin G. Kulasekararaj, MBBS, MD MRCP, FRCPath, Kavita Raj, MD PhD, Donal McLornan, Judith Marsh, MD, Victoria Potter, Joanna Large, Isabel Duggins, Aytug Kizilors, PhD, Nicholas Lea, PhD, Antonio Pagliuca, MD, Ghulam Mufti, DM, FRCP, FRCPath, Hugues De Lavallade

Blood (2017) 130 (Supplement 1): 5250.

https://doi.org/10.1182/blood.V130.Suppl_1.5250.5250

Published: 2017

Journal Articles

Coversin, a Novel C5 Complement Inhibitor, Is Safe and Effective in the Treatment of PNH: Results of a Phase II Clinical Trial

Anita Hill, MBChB (Hons), PhD, Wynne Weston-Davies, MB FRCS, Miles Nunn, PhD, Tadeusz Robak, MD PhD, Jerzy Windyga, MD, Andrzej Hellmann, MD PhD DSc, Austin G. Kulasekararaj, MBBS, MD MRCP, FRCPath, Agniezka Piekarska, Anna Szmigielska-Kaplon, Morag Griffin, Talha Munir

Blood (2017) 130 (Supplement 1): 4747.

https://doi.org/10.1182/blood.V130.Suppl_1.4747.4747

Published: 2017

NARROW

Treatment outcomes of complement protein C5 inhibition in 509 UK patients with paroxysmal nocturnal hemoglobinuria

AI for AA: machine learning makes an entry

Consensus proposal for revised International Working Group 2023 response criteria for higher-risk myelodysplastic syndromes

Germ line DDX41 mutations define a unique subtype of myeloid neoplasms

Phase 2 study of danicopan in patients with paroxysmal nocturnal hemoglobinuria with an inadequate response to eculizumab

Two Currently Recruiting Randomized Phase III Trials: COMMODORE 1 and 2 Evaluating Crovalimab Vs Eculizumab in Patients with Paroxysmal Nocturnal Hemoglobinuria with or without Current Anti-Complement Therapy

NGS Evaluation of the Eqol-MDS Trial: Preliminary Analysis of Eltrombopag for Thrombocytopenia of Low-Risk MDS

Immunogenicity of Covid-19 Vaccination in Subjects with Myelodysplastic Syndromes

Predictors for Improvement in Patient-Reported Outcomes: Post-Hoc Analysis of a Phase 3 Randomized, Open-Label Study of Eculizumab and Ravulizumab in Complement Inhibitor-Naïve Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH)

Ravulizumab (ALXN1210) vs eculizumab in C5-inhibitor–experienced adult patients with PNH: the 302 study

A Review of 1000 Molecular Investigations of Rare Inherited Anaemia and Related Conditions with the Red Cell Gene Panel

Efficacy of Eculizumab in Pediatric Patients with Paroxysmal Nocturnal Hemoglobinuria in the International PNH Registry

Prognostic Value of Clone Size in Paroxysmal Nocturnal Hemoglobinuria (PNH) for Thrombotic Events in Untreated Patients in the International PNH Registry

Long-Term Follow-up of the Randomized Controlled Study in Patients with Newly Diagnosed Severe Aplastic Anemia Treated with ATG, Cyclosporine, with or without G-CSF: On Behalf of the SAA Working Party of the EBMT

A Prospective Analysis of Breakthrough Hemolysis in 2 Phase 3 Randomized Studies of Ravulizumab (ALXN1210) Versus Eculizumab in Adults with Paroxysmal Nocturnal Hemoglobinuria

Results from a Phase 3, Multicenter, Non-Inferiority Study of Ravulizumab (ALXN1210) Versus Eculizumab in Adult Patients with Paroxysmal Nocturnal Hemoglobinuria Currently Treated with Eculizumab

Prognostic and Predictive Impact of Small PNH Clones in a Large Cohort of Patients with Myelodysplastic Syndromes and Aplastic Anemia: A Single-Center Experience

Neoantigens in MDS Are Associated with Two Novel CD4+ T Cell Subsets and Improved Overall Survival

Low-Dose Second Generation TKI Is an Effective Approach to Reduce TKI Related Side Effects and Toxicity While Preserving Molecular Response in CML Patients with TKI Intolerance

Coversin, a Novel C5 Complement Inhibitor, Is Safe and Effective in the Treatment of PNH: Results of a Phase II Clinical Trial

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only